BioCentury
ARTICLE | Clinical News

AZ updates endpoints, timeline of MYSTIC trial

January 18, 2017 1:01 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) updated its analysis plan for its Phase III MYSTIC trial of durvalumab (MEDI4736) and tremelimumab (CP-675) as first-line therapy for non-small cell lung cancer (NSCLC). The trial's primary endpoints will now include overall survival (OS) for durvalumab monotherapy, as well as existing primary endpoints evaluating OS and progression-free survival (PFS) for the combination.

AZ now expects PFS data in mid-2017 and OS data next year "at the latest." It had previously guided for PFS data in 1H17...

BCIQ Company Profiles

AstraZeneca plc

BCIQ Target Profiles

CTLA4

PD-L1